SG11201807977XA - Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor - Google Patents

Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Info

Publication number
SG11201807977XA
SG11201807977XA SG11201807977XA SG11201807977XA SG11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA SG 11201807977X A SG11201807977X A SG 11201807977XA
Authority
SG
Singapore
Prior art keywords
heidelberg
international
checkpoint inhibitor
cancer therapy
combined
Prior art date
Application number
SG11201807977XA
Inventor
Barbara Leuchs
Antonio Marchini
Jean Rommelaere
Assia Angelova
Dirk JÄGER
Wolfgang Wick
Michael Dahm
Original Assignee
Deutsches Krebsforsch
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls filed Critical Deutsches Krebsforsch
Publication of SG11201807977XA publication Critical patent/SG11201807977XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111 HO EOM 0111 10011111110111 I 111E1111 MI International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date .... ...,,, 5 October 2017 (05.10.2017) IN I PO I P CT WO 2017/167626 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/00 (2006.01) A61K 35/768 (2015.01) kind A61K 39/395 (2006.01) AO, BZ, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2017/056886 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, 22 March 2017 (22.03.2017) MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, ZA, ZM, ZW. TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: EP16163555.2 1 April 2016 (01.04.2016) EP (84) Designated States (unless otherwise indicated, for every EP16020193.5 27 May 2016 (27.05.2016) EP kind GM, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicants: DEUTSCHES KREBSFORSCHUNG- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: LEUCHS, Barbara; SZENTRUM [DE/DE]; Im Neuenheimer Feld, 69120 TJ, Heidelberg (DE). RUPRECHT-KARLS-UNIVERSITAT DK, HEIDELBERG [DE/DE]; Grabengasse 1, 69117 Heidel- LV, berg (DE). SM, GW, KM, ML, MR, NE, SN, TD, TG). Handschuhsheimer Land- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — strasse 79, 69121 Heidelberg (DE). MARCHINI, Anto- Published: nio; Im Gabelacker 15, 69120 Heidelberg (DE). ROM- — MELAERE, Jean; SchioB Wolfsbrunnenweg 11, 69118 with international search report (Art. 21(3)) Heidelberg (DE). ANGELOVA, Assia; Bergheimerstr. 59, — before the expiration of the time limit for amending the = 69115 Heidelberg (DE). JAGER, Dirk; Hauptstr. 99, claims and to be republished in the event of receipt of 55246 Mainz-Kostheim (DE). WICK, Wolfgang; Schloss- amendments (Rule 48.2(h)) Wolfsbrunnenweg 1, 69117 Heidelberg (DE). — with sequence listing part of description (Rule 5.2(a)) = Agent: HUBER & SCHUSSLER; Truderinger Strasse (74) _ 246, 81825 Munich (DE). = = = = = = = = = = 1-1 ei IN 1-1 IN 1-1 0 \" (54) Title: CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR C ) „,.. (57) : The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an on - .,- colytic virus and the use of said combination for the treatment of cancer.
SG11201807977XA 2016-04-01 2017-03-22 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor SG11201807977XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163555 2016-04-01
EP16020193.5A EP3225253A1 (en) 2016-04-01 2016-05-27 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
PCT/EP2017/056886 WO2017167626A1 (en) 2016-04-01 2017-03-22 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
SG11201807977XA true SG11201807977XA (en) 2018-10-30

Family

ID=55650316

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807977XA SG11201807977XA (en) 2016-04-01 2017-03-22 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Country Status (16)

Country Link
US (2) US11027013B2 (en)
EP (1) EP3225253A1 (en)
JP (1) JP6689400B2 (en)
KR (1) KR102195055B1 (en)
CN (1) CN109069601B (en)
AU (1) AU2017242089B2 (en)
BR (1) BR112018069927A2 (en)
CA (1) CA3019634A1 (en)
CL (1) CL2018002793A1 (en)
EA (1) EA037354B1 (en)
IL (1) IL261554B (en)
LT (1) LT3436058T (en)
MX (1) MX2018010709A (en)
SG (1) SG11201807977XA (en)
WO (1) WO2017167626A1 (en)
ZA (1) ZA201805548B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110461346A (en) * 2017-03-15 2019-11-15 美国安进公司 Oncolytic virus is independent or the purposes for being used for treating cancer is combined with checkpoint inhibitor
CN109022616B (en) * 2018-07-25 2021-11-12 广州烨善生物科技有限公司 Probe for detecting oncolytic virus and application thereof
EP3657172A1 (en) 2018-11-22 2020-05-27 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample
AU2020214412A1 (en) * 2019-02-01 2021-08-12 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
CN113747947A (en) * 2019-02-28 2021-12-03 沙塔克实验室有限公司 Combination therapy
CN111154806A (en) * 2020-01-08 2020-05-15 深圳普菲科生命科技有限公司 Oncolytic virus vector system embedded with exogenous super cell factor and application of oncolytic virus vector system in medicine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
US7179456B2 (en) * 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
ES2402138T3 (en) 2007-12-28 2013-04-29 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Cancer therapy with a parvovirus combined with chemotherapy
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
EP2266587A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oncolytic virotherapy for prevention of tumor recurrence
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
EP2366398A1 (en) 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
EP2397542A1 (en) 2010-06-17 2011-12-21 Deutsches Krebsforschungszentrum Modified parvovirus having enhanced anti-tumour efficacy
EP2404609A1 (en) * 2010-07-07 2012-01-11 Deutsches Krebsforschungszentrum Use of parvovirus for eliminating cancer stem cells (CSCs)
EP2535055A1 (en) * 2011-06-15 2012-12-19 Deutsches Krebsforschungszentrum Oncolytic virotherapy for therapy of bone cancer
US20130129678A1 (en) * 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
LT2785375T (en) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
EP2829284A1 (en) * 2013-07-22 2015-01-28 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor
ME03558B (en) 2014-03-14 2020-07-20 Novartis Ag Antibody molecules to lag-3 and uses thereof
AU2015259510B2 (en) 2014-05-13 2020-10-01 Bavarian Nordic A/S Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
JP6843736B2 (en) * 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ Combination of oncolytic virus and immune checkpoint modulator
EP3108892A1 (en) * 2015-06-23 2016-12-28 Deutsches Krebsforschungszentrum Parvovirus formulation for treating tumors

Also Published As

Publication number Publication date
JP6689400B2 (en) 2020-04-28
WO2017167626A1 (en) 2017-10-05
CL2018002793A1 (en) 2019-02-01
AU2017242089B2 (en) 2019-08-15
IL261554A (en) 2018-10-31
ZA201805548B (en) 2019-11-27
US20190117768A1 (en) 2019-04-25
NZ745264A (en) 2020-10-30
CA3019634A1 (en) 2017-10-05
LT3436058T (en) 2020-02-10
EP3225253A1 (en) 2017-10-04
BR112018069927A2 (en) 2019-02-05
KR20180127468A (en) 2018-11-28
US11027013B2 (en) 2021-06-08
IL261554B (en) 2022-05-01
KR102195055B1 (en) 2020-12-24
MX2018010709A (en) 2019-01-14
AU2017242089A1 (en) 2018-08-30
US11964015B2 (en) 2024-04-23
CN109069601A (en) 2018-12-21
EA037354B1 (en) 2021-03-17
US20210228714A1 (en) 2021-07-29
JP2019510769A (en) 2019-04-18
EA201891679A1 (en) 2019-04-30
CN109069601B (en) 2022-05-10

Similar Documents

Publication Publication Date Title
SG11201807977XA (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
SG11201908547VA (en) Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
SG11201811432WA (en) Rna for cancer therapy
SG11201806340YA (en) Zika virus vaccine
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201805120YA (en) Zika virus vaccine
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201408261UA (en) Syringe
SG11201807912SA (en) Vaccine against rsv
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201407200TA (en) Liquid formulation
SG11201909520VA (en) Rna for treatment of autoimmune diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201901351UA (en) A patient interface, system and method
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201406987UA (en) Glucokinase activator compositions for the treatment of diabetes
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases